Cx 611

Drug Profile

Cx 611

Alternative Names: Adipose-derived allogenic stem cell therapy - TiGenix NV; Cx611; eASC - TiGenix

Latest Information Update: 04 Nov 2015

Price : $50

At a glance

  • Originator Cellerix
  • Developer TiGenix
  • Class Antirheumatics; Antiseptics; Stem cell therapies
  • Mechanism of Action Cell replacements; Cytokine modulators; Immunomodulators; Inflammation mediator inhibitors; Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Rheumatoid arthritis
  • Phase I Sepsis

Most Recent Events

  • 02 Nov 2015 TiGenix plans a phase Ia/IIb trial in Sepsis in Europe
  • 23 Sep 2015 Clinical development for Rheumatoid Arthritis is ongoing in Spain
  • 28 May 2015 Adverse events data from a phase I trial in Sepsis (In volunteers) released by TiGenix
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top